ALB and hepatocellular carcinoma: This study evaluated the hepatoprotective effects and safety profile of donafenib combined with transarterial chemoembolization (TACE) in unresectable hepatocellular carcinoma (HCC) through analysis of albumin-bilirubin (ALBI) score modifications.